The ATAC (Arimidex™, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment
- 31 October 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (15) , 1984-1986
- https://doi.org/10.1016/s0959-8049(02)00154-5
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer.BMJ, 1986